Skip to main content
. Author manuscript; available in PMC: 2015 Dec 5.
Published in final edited form as: Eur J Pharmacol. 2014 Oct 23;744:211–219. doi: 10.1016/j.ejphar.2014.09.044

Figure 6. CAP pretreatment alters the subcellular disposition of AP-2 in Neuro 2a cells.

Figure 6

Confocal micrographs represent the immunostaining for AP-2 µ1 in control and CAP treated wild type Neuro 2a cells and TRPV1 expressing Neuro 2a cells.